First Time Loading...

Aprea Therapeutics Inc
NASDAQ:APRE

Watchlist Manager
Aprea Therapeutics Inc Logo
Aprea Therapeutics Inc
NASDAQ:APRE
Watchlist
Price: 5.35 USD 3.48% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

APRE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. [ Read More ]

The intrinsic value of one APRE stock under the Base Case scenario is 0.61 USD. Compared to the current market price of 5.35 USD, Aprea Therapeutics Inc is Overvalued by 89%.

Key Points:
APRE Intrinsic Value
Base Case
0.61 USD
Overvaluation 89%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Aprea Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling APRE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Aprea Therapeutics Inc

Provide an overview of the primary business activities
of Aprea Therapeutics Inc.

What unique competitive advantages
does Aprea Therapeutics Inc hold over its rivals?

What risks and challenges
does Aprea Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Aprea Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aprea Therapeutics Inc.

Provide P/S
for Aprea Therapeutics Inc.

Provide P/E
for Aprea Therapeutics Inc.

Provide P/OCF
for Aprea Therapeutics Inc.

Provide P/FCFE
for Aprea Therapeutics Inc.

Provide P/B
for Aprea Therapeutics Inc.

Provide EV/S
for Aprea Therapeutics Inc.

Provide EV/GP
for Aprea Therapeutics Inc.

Provide EV/EBITDA
for Aprea Therapeutics Inc.

Provide EV/EBIT
for Aprea Therapeutics Inc.

Provide EV/OCF
for Aprea Therapeutics Inc.

Provide EV/FCFF
for Aprea Therapeutics Inc.

Provide EV/IC
for Aprea Therapeutics Inc.

Show me price targets
for Aprea Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Aprea Therapeutics Inc?

How accurate were the past Revenue estimates
for Aprea Therapeutics Inc?

What are the Net Income projections
for Aprea Therapeutics Inc?

How accurate were the past Net Income estimates
for Aprea Therapeutics Inc?

What are the EPS projections
for Aprea Therapeutics Inc?

How accurate were the past EPS estimates
for Aprea Therapeutics Inc?

What are the EBIT projections
for Aprea Therapeutics Inc?

How accurate were the past EBIT estimates
for Aprea Therapeutics Inc?

Compare the revenue forecasts
for Aprea Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aprea Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aprea Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aprea Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Aprea Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aprea Therapeutics Inc with its peers.

Analyze the financial leverage
of Aprea Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Aprea Therapeutics Inc.

Provide ROE
for Aprea Therapeutics Inc.

Provide ROA
for Aprea Therapeutics Inc.

Provide ROIC
for Aprea Therapeutics Inc.

Provide ROCE
for Aprea Therapeutics Inc.

Provide Gross Margin
for Aprea Therapeutics Inc.

Provide Operating Margin
for Aprea Therapeutics Inc.

Provide Net Margin
for Aprea Therapeutics Inc.

Provide FCF Margin
for Aprea Therapeutics Inc.

Show all solvency ratios
for Aprea Therapeutics Inc.

Provide D/E Ratio
for Aprea Therapeutics Inc.

Provide D/A Ratio
for Aprea Therapeutics Inc.

Provide Interest Coverage Ratio
for Aprea Therapeutics Inc.

Provide Altman Z-Score Ratio
for Aprea Therapeutics Inc.

Provide Quick Ratio
for Aprea Therapeutics Inc.

Provide Current Ratio
for Aprea Therapeutics Inc.

Provide Cash Ratio
for Aprea Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Aprea Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Aprea Therapeutics Inc?

What is the current Free Cash Flow
of Aprea Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aprea Therapeutics Inc.

Financials

Balance Sheet Decomposition
Aprea Therapeutics Inc

Current Assets 22.5m
Cash & Short-Term Investments 21.6m
Other Current Assets 914.3k
Non-Current Assets 129.1k
PP&E 88.4k
Other Non-Current Assets 40.7k
Current Liabilities 4.4m
Accounts Payable 1.7m
Accrued Liabilities 2.2m
Other Current Liabilities 529k
Efficiency

Earnings Waterfall
Aprea Therapeutics Inc

Revenue
583.2k USD
Operating Expenses
-16.1m USD
Operating Income
-15.5m USD
Other Expenses
1.2m USD
Net Income
-14.3m USD

Free Cash Flow Analysis
Aprea Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

APRE Profitability Score
Profitability Due Diligence

Aprea Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

38/100
Profitability
Score

Aprea Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

APRE Solvency Score
Solvency Due Diligence

Aprea Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Aprea Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

APRE Price Targets Summary
Aprea Therapeutics Inc

Wall Street analysts forecast APRE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for APRE is 15.98 USD with a low forecast of 11.11 USD and a high forecast of 21 USD.

Lowest
Price Target
11.11 USD
108% Upside
Average
Price Target
15.98 USD
199% Upside
Highest
Price Target
21 USD
293% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

APRE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

APRE Price
Aprea Therapeutics Inc

1M 1M
-10%
6M 6M
+39%
1Y 1Y
+40%
3Y 3Y
-94%
5Y 5Y
-99%
10Y 10Y
-99%
Annual Price Range
5.35
52w Low
2.89
52w High
8.46
Price Metrics
Average Annual Return -22.48%
Standard Deviation of Annual Returns 99.17%
Max Drawdown -100%
Shares Statistics
Market Capitalization 20m USD
Shares Outstanding 3 736 670
Percentage of Shares Shorted 2.19%

APRE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Aprea Therapeutics Inc Logo
Aprea Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

20m USD

Dividend Yield

0%

Description

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2019-10-03. The firm is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The firm's lead product, eprenetapopt (APR-246), is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator that is being developed in an oral dosage form.

Contact

MASSACHUSETTS
Boston
535 Boylston St
+16095104718.0
https://www.aprea.com/

IPO

2019-10-03

Employees

16

Officers

Head of Technology
Dr. Dansu Li Ph.D.
Senior VP & Chief Scientific Officer
Dr. Lars B. Abrahmsen Ph.D.
Head of Pharmacology Development
Dr. Michel Afargan Ph.D.
Chief Business Advisor
Mr. Ze'ev Weiss B.Sc., C.P.A.
Controller
Ms. Andrea Epstein

See Also

Discover More
What is the Intrinsic Value of one APRE stock?

The intrinsic value of one APRE stock under the Base Case scenario is 0.61 USD.

Is APRE stock undervalued or overvalued?

Compared to the current market price of 5.35 USD, Aprea Therapeutics Inc is Overvalued by 89%.